In certain cases, modulating the number of ITAMs in CD3ζ or employing other TCR subunits such as CD3δ, CD3γ, or CD3ε can regulate T cell activation and IFN-γ release, thereby mitigating toxicity and impeding the progression of SLE (208). This evidence concerns the gene IFNG and systemic lupus erythematosus.